Evidence map›Paper›PMID 33153037›Full record

ArticleCancers2020

Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer.

Mercedes Herrera, Artur Mezheyeuski, Lisa Villabona, Sara Corvigno, Carina Strell, Christian Klein, Gabriele Hölzlwimmer, Bengt Glimelius, Giuseppe Masucci, Tobias Sjöblom and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. [The Three-dimensional Environment of Type Ⅰ Collagen Gels With Varying Stiffness Modulates the Immunological Functions of NK Cells].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. CD8Frontiers in immunology · 2022
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Mercedes HerreraOncology and Pathology Department, Karolinska Institutet, 17164 Stockholm, Sweden.
Artur MezheyeuskiDepartment of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.
Lisa VillabonaOncology and Pathology Department, Karolinska Institutet, 17164 Stockholm, Sweden.
Sara CorvignoDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Carina StrellDepartment of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.
Christian KleinRoche Innovation Center Zurich, Roche Pharma Research and Early Development pRED, 8952 Schlieren, Switzerland.ORCID 0000-0001-7594-7280
Gabriele HölzlwimmerRoche Innovation Center Munich, Department of Pathology and Tissue Analytics, Roche Pharma Research and Early Development pRED, 82377 Penzberg, Germany.ORCID 0000-0001-5775-6093
Bengt GlimeliusDepartment of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.
Giuseppe MasucciOncology and Pathology Department, Karolinska Institutet, 17164 Stockholm, Sweden.ORCID 0000-0002-9583-2306
Tobias SjöblomDepartment of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.ORCID 0000-0001-6668-4140
Arne ÖstmanOncology and Pathology Department, Karolinska Institutet, 17164 Stockholm, Sweden.
Karolinska Institutet · SEUppsala University · SERoche Pharma AG (Germany) · DERoche (Switzerland) · CHThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inter-case variations in immune cell and fibroblast composition are associated with prognosis in solid tumors, including colon cancer. A series of experimental studies suggest immune-modulatory roles of marker-defined fibroblast populations, including FAP-positive fibroblasts. These studies imply that the fibroblast status of tumors might affect the prognostic significance of immune-related features. Analyses of a population-based colon cancer cohort demonstrated good prognosis associations of FAP intensity and CD8a density. Notably, a significant prognostic interaction was detected between these markers (

Indexed as

cancer associated fibroblastscolon cancerprognosisT lymphocytestumor microenvironment

Identifiers

PMID33153037
PMCPMC7693786
OpenAlexW3096226787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.